【歌礼制药-B(01672.HK)宣布ASC47单药疗法澳大利亚Ib期研究取得积极顶线结果及ASC47联合司美格鲁肽的新药临床试验申请获美国FDA批准】歌礼制药-B(01672.HK)宣布ASC47澳大利亚Ib期低密度脂蛋白胆固醇 (LDL-C)偏高的健康受试者(第一部分)和肥胖症患者(第二部分)中的单次皮下注射研究(NCT06427590)取得令人振奋的药代动力学和减重数据。

金融界
12 Mar
歌礼制药-B(01672.HK)宣布ASC47澳大利亚Ib期低密度脂蛋白胆固醇 (LDL-C)偏高的健康受试者(第一部分)和肥胖症患者(第二部分)中的单次皮下注射研究(NCT06427590)取得令人振奋的药代动力学和减重数据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10